Japan Tobacco Inc. (JT) (TSE: 2914) today announces the results of a clinical study showing the biomarker of potential harm measured in Ploom TECH users was significantly different from those in combustible cigarette smokers and instead closer to those in people who have never used any tobacco or nicotine containing products (never-smokers). The study was conducted in consultation with medical advisor, Yuji Kumagai, M.D., Ph.D. Professor, Kitasato Clinical Research Center.
“Although further research is required, this new clinical study again highlights that Ploom TECH has the potential of reducing the health risks associated with smoking,” said Ian Jones, Vice President, R&D Principal Scientist, JTI.[…]